Loading organizations...
§ Private Profile · San Francisco, CA, USA
Threshold Pharm is a company.
Key people at Threshold Pharm.
Threshold Pharmaceuticals developed oncology therapies by exploiting the unique biochemistry of tumors. Its primary product, TH-302, was a hypoxia-activated prodrug designed to selectively attack cancer cells in oxygen-deprived regions of solid tumors. This innovative approach activated a potent cytotoxic agent, bromo-isophosphoramide mustard, within the hypoxic tumor microenvironment, enhancing therapeutic precision.
The company was founded in 2001 by George Tidmarsh, driven by an insight into leveraging distinct metabolic characteristics of cancerous growths. His vision was to create drugs that remained inactive until exposed to low-oxygen conditions prevalent in aggressive tumors, enhancing therapeutic precision. Tidmarsh's background in drug development informed this novel strategy.
Threshold Pharmaceuticals aimed to provide new treatment options for patients with various solid tumors where hypoxic conditions contribute to disease progression. Its vision involved pioneering a class of cancer therapeutics that precisely targeted the tumor microenvironment, striving to improve patient prognosis and quality of life.
Key people at Threshold Pharm.
Threshold Pharmaceuticals is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of small molecule therapeutics that selectively target tumor cells and the tumor microenvironment. Its approach, known as Metabolic Targeting, aims to treat solid tumors and certain other diseases more effectively and with less toxicity than conventional therapies. The company primarily serves cancer patients, focusing on indications such as soft tissue sarcoma, pancreatic cancer, non-small cell lung cancer, melanoma, and multiple myeloma. Threshold’s pipeline includes drug candidates like evofosfamide and tarloxotinib, which have been evaluated in multiple Phase II and III clinical trials. The company operates mainly in the United States and Germany, with headquarters in South San Francisco, California[1][2][3].
Founded in 2001, Threshold Pharmaceuticals emerged with a focus on developing tumor-targeted therapies that exploit the unique metabolic environment of cancer cells. The founding team brought expertise in oncology drug development and molecular targeting. Early traction came from advancing evofosfamide (TH-302), a hypoxia-activated prodrug designed to selectively kill hypoxic tumor cells, into late-stage clinical trials. Collaborations with institutions like the National Cancer Institute further supported its research pipeline. Over time, Threshold expanded its focus to include other oncology indications and diagnostic agents targeting tumor hypoxia and microenvironment[1][2][4].
Threshold Pharmaceuticals rides the trend of precision oncology and targeted cancer therapies, which aim to improve treatment outcomes by focusing on tumor-specific characteristics such as hypoxia and metabolic vulnerabilities. The timing is critical as oncology treatment increasingly shifts toward personalized medicine, combining targeted drugs with diagnostics to optimize therapy. Market forces favor companies that can demonstrate improved efficacy with reduced side effects, addressing unmet needs in difficult-to-treat cancers. Threshold’s work contributes to the broader ecosystem by advancing hypoxia-activated prodrugs and companion diagnostics, potentially influencing future standards of care in oncology[1][2][3].
Looking ahead, Threshold Pharmaceuticals’ future depends on the successful commercialization of its lead candidates and the ability to demonstrate clear clinical benefits in ongoing and future trials. Trends shaping its journey include the growing emphasis on tumor microenvironment targeting, integration of diagnostic imaging for personalized treatment, and potential expansion into immuno-oncology and other therapeutic areas. As the oncology landscape evolves, Threshold’s specialized approach could position it as a key player in developing safer, more effective cancer therapies, provided it navigates regulatory and competitive challenges effectively[1][2][4].
